KAIROS PHARMA, LTD. Cash and Cash Equivalents
KAIROS PHARMA, LTD. (KAPA) had Cash and Cash Equivalents of $2.63 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-12
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $2.63M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $3.67M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $4.49M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $5.58M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $2.63M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $3.67M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $4.49M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $5.58M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $3.03M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.62M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.27M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |